Cite
P.07.15 INFLIXIMAB TROUGH LEVELS AND ANTI-DRUG ANTIBODIES AFTER INDUCTION AS PREDICTIVE FACTORS OF LONG TERM CLINICAL REMISSION
MLA
Giorgia Bodini, et al. “P.07.15 Infliximab Trough Levels and Anti-Drug Antibodies After Induction as Predictive Factors of Long Term Clinical Remission.” Digestive and Liver Disease, vol. 48, Feb. 2016, p. e163. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........1ddd8136f6242cda283b45204ba3c10f&authtype=sso&custid=ns315887.
APA
Giorgia Bodini, C. De Maria, Edoardo Savarino, V. Savarino, L. Del Nero, I. Baldissarro, & Edoardo G. Giannini. (2016). P.07.15 Infliximab Trough Levels and Anti-Drug Antibodies After Induction as Predictive Factors of Long Term Clinical Remission. Digestive and Liver Disease, 48, e163.
Chicago
Giorgia Bodini, C. De Maria, Edoardo Savarino, V. Savarino, L. Del Nero, I. Baldissarro, and Edoardo G. Giannini. 2016. “P.07.15 Infliximab Trough Levels and Anti-Drug Antibodies After Induction as Predictive Factors of Long Term Clinical Remission.” Digestive and Liver Disease 48 (February): e163. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........1ddd8136f6242cda283b45204ba3c10f&authtype=sso&custid=ns315887.